Skip to main content



15-02-2022 | Rheumatology | News | Article

Intensified anifrolumab regimen may warrant further investigation for lupus nephritis

Findings from the phase 2 TULIP-LN trial suggest that add-on treatment with an intensified regimen of anifrolumab, a type I interferon receptor inhibitor, may improve some outcomes for patients with lupus nephritis.

29-08-2021 | Diabetes | News | Article

HF and CKD doubly dangerous for people with type 2 diabetes

Rates of hospitalization and mortality are increased in people with type 2 diabetes who also have heart failure or chronic kidney disease, and more so if they have both conditions, say researchers.

18-12-2020 | Cardiovascular | News | Article

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

01-09-2020 | Diabetes | News | Article

DAPA-CKD shows dapagliflozin benefits regardless of diabetes

The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.

23-04-2020 | Diabetes | News | Article

Real-world evidence for renoprotective effects of GLP-1 receptor agonists

People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.

20-12-2019 | Diabetes | News | Article

CVD-REAL 3: Renal benefits of SGLT2 inhibitors confirmed in real-world study

Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.

17-04-2019 | Diabetes | News | Article

SONAR results support atrasentan for preserving renal function in type 2 diabetes

The endothelin receptor antagonist atrasentan may reduce the risk for kidney disease progression among certain high-risk patients with type 2 diabetes and kidney disease, indicate findings from the SONAR trial.

09-08-2016 | Diabetes | News | Article

Steady prevalence masks changes in diabetic kidney disease

Patients with diabetic kidney disease have become less likely to have albuminuria but more likely to have a reduced estimated glomerular filtration rate over recent years, shows an analysis of NHANES data.

16-06-2016 | Arrhythmia | News | Article

Worsening renal function linked to increased cardiovascular risk in AF

Patients with atrial fibrillation and declining renal function are at increased risk of subsequent stroke or systemic embolism, major bleeding and death, US researchers report.

15-06-2016 | Diabetes | News | Article

Empagliflozin offers long-term renal protection in Type 2 diabetes

The sodium–glucose cotransporter 2 inhibitor empagliflozin slows renal progression and averts clinical events, shows further analysis of the EMPA-REG OUTCOME trial.

01-06-2016 | Stroke | News | Article

Researchers call for more accurate renal assessment in stroke patients

Unrecognised renal insufficiency is common among patients with acute stroke and is associated with a significantly increased risk of in-hospital mortality or severe disability at discharge, say researchers.

31-05-2016 | Diabetes | News | Article

Renal function trajectories predict CV events in diabetes patients

Steeper declines in renal function over time are associated with greater increases in the risk of major cardiovascular events among patients with Type 2 diabetes, research shows.

26-05-2016 | Acute coronary syndromes | News | Article

CKD status does not affect health status outcomes after AMI

Chronic kidney disease does not accentuate the decline in health status often experienced by patients after acute myocardial infarction, US study data show.

25-05-2016 | Cardiology | News | Article

Sodium excretion linked to CVD risk in chronic kidney disease

High levels of sodium excretion are associated with a significantly increased risk of cardiovascular disease in patients with chronic kidney disease (CKD), US study findings indicate.

10-03-2016 | HBV | News | Article

Renal risk factors for NA-treated HBV patients identified

A South Korean research team has identified several clinical and medical factors associated with renal function decline in patients with chronic hepatitis B virus infection treated with oral nucleos(t)ide analogues.

15-12-2014 | Oncology | Article

RCC renal function independent of axitinib-induced proteinuria

Treatment with the vascular endothelial growth factor receptor inhibitor axitinib does not adversely affect renal function in patients with metastatic renal cell carcinoma even in the presence of proteinuria, a Japanese study indicates.

15-12-2014 | Oncology | Article

Metastatic RCC patients may benefit from sequential TKI strategy

For patients with metastatic renal cell carcinoma, sequential tyrosine kinase inhibitor therapy may be better option than changing to a mammalian target of rapamycin inhibitor, research suggests.

17-11-2014 | Oncology | Article

Nonlinear correlation between axitinib dose, dBP increase

A pharmacokinetic–pharmacodynamic model shows that diastolic blood pressure rises with increasing doses of axitinib in patients with metastatic renal cell carcinoma, US researchers report, although this relationship is not linear.

17-11-2014 | Oncology | Article

Statin use linked to improved RCC surgery outcomes

Statin use at the time of surgery is associated with improved overall survival and disease-specific survival in patients with renal cell carcinoma of any stage, US researchers report.

12-11-2014 | Oncology | Article

Cytoreductive nephrectomy benefits limited by preoperative risk factors

The survival benefit of cytoreductive nephrectomy when used in conjunction with targeted therapy for metastatic renal cell carcinoma depends on the number of preoperative risk factors a patient carries, study findings indicate.